Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is effective in patients with melanoma, although long-term responses seem restricted in patients who have complete remissions. Many patients develop secondary resistance to TIL-ACT but the involved mechanisms are unclear. In this study, we describe a case of secondary resistance to TIL-ACT possibly due to intratumoral heterogeneity and selection of a resistant tumor cell clone by the transferred T cells. To the best our knowledge, this is the first case of clonal selection of a pre-existing nondominant tumor cell clone; this report demonstrates the mechanism involved in secondary resistance to TIL-ACT that can potentially change current clinical practice because it advocates for T-cell collection from multiple tumor sites and analysis of tumor heterogeneity before treatment with TIL-ACT.
Supplementary Figure 2. Regressing soft tissue metastasis (Biopsy 3 weeks after TIL transfer). Vital tumor areas (SOX10) are densely infiltrated by CD8 positive tumor infiltrating lymphocytes as shown by immunohistochemistry.
Supplementary Figure 4. Progressing lung metastasis (Wedge resection 61 weeks after TIL transfer). The resected lung metastasis is Melan-A positive without any desmoplastic component.